Free Trial
NASDAQ:ANIX

Anixa Biosciences (ANIX) Stock Price, News & Analysis

Anixa Biosciences logo
$2.60 -0.02 (-0.57%)
As of 11:27 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Anixa Biosciences Stock (NASDAQ:ANIX)

Key Stats

Today's Range
$2.56
$2.64
50-Day Range
$2.38
$3.15
52-Week Range
$2.07
$4.20
Volume
4,330 shs
Average Volume
89,142 shs
Market Capitalization
$83.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Anixa Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

ANIX MarketRank™: 

Anixa Biosciences scored higher than 43% of companies evaluated by MarketBeat, and ranked 651st out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Anixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Anixa Biosciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Anixa Biosciences' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Anixa Biosciences is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Anixa Biosciences is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Anixa Biosciences has a P/B Ratio of 4.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Anixa Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    1.24% of the float of Anixa Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Anixa Biosciences has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Anixa Biosciences has recently increased by 5.42%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Anixa Biosciences does not currently pay a dividend.

  • Dividend Growth

    Anixa Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.24% of the float of Anixa Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Anixa Biosciences has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Anixa Biosciences has recently increased by 5.42%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Anixa Biosciences has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Anixa Biosciences this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for ANIX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Anixa Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    25.30% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 29.13% of the stock of Anixa Biosciences is held by institutions.

  • Read more about Anixa Biosciences' insider trading history.
Receive ANIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ANIX Stock News Headlines

Elon Musk’s Frightening Warning Forces Trump’s Hand
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.
See More Headlines

ANIX Stock Analysis - Frequently Asked Questions

Anixa Biosciences' stock was trading at $2.32 at the beginning of the year. Since then, ANIX stock has increased by 12.5% and is now trading at $2.61.
View the best growth stocks for 2025 here
.

Anixa Biosciences, Inc. (NASDAQ:ANIX) announced its quarterly earnings data on Tuesday, June, 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01.

Anixa Biosciences' top institutional investors include D.A. Davidson & CO. (1.91%) and Private Advisor Group LLC (0.04%). Insiders that own company stock include Lewis H Titterton Jr, Amit Kumar, Arnold M Baskies and Michael Catelani.
View institutional ownership trends
.

Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Anixa Biosciences investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Coty (COTY), AbbVie (ABBV), Adverum Biotechnologies (ADVM) and Avino Silver & Gold Mines (ASM).

Company Calendar

Today
5/30/2025
Last Earnings
6/03/2025
Next Earnings (Estimated)
6/03/2025
Fiscal Year End
10/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ANIX
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$10.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+246.2%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.55 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$210,000.00
Price / Cash Flow
N/A
Book Value
$0.59 per share
Price / Book
4.41

Miscellaneous

Free Float
24,051,000
Market Cap
$83.71 million
Optionable
Optionable
Beta
0.43
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ANIX) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners